CompletedNot Applicable

Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

1,120 participantsStarted 2007-01

Plain-language summary

The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg) to a large number of patients in daily medical practice.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with the following diseases for whom oral administration is not feasible: Gastric ulcer, duodenal ulcer, acute stress gastritis, and acute gastric mucosal lesion (all of which should be accompanied by bleeding). Exclusion Criteria: \-

What they're measuring

Number of Participants Reporting One or More Adverse Drug Reactions

Timeframe: Baseline up to Week 9

Number of Participants Reporting One or More Serious Adverse Drug Reactions

Timeframe: Baseline up to Week 9

Trial details

NCT IDNCT02151786

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2010-03

Results submitted2016-01-24

View on ClinicalTrials.gov More Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions trials